Herpesviridae infectious disease

disease
On this page

Also known as Herpesviridae caused disease or disorderHerpesviridae disease or disorderHerpesviridae infectionHerpesviridae infectionsHerpesvirus infectionHerpesvirus infectionsinfection, Herpesviridaeinfection, Herpesvirusinfections, Herpesviridaeinfections, Herpesvirus

Summary

Herpesviridae infectious disease (MONDO:0005794) is a disease (an umbrella term covering 8 Mondo subtypes) and 10 clinical trials. Top therapeutic interventions include ganciclovir and valacyclovir. A subtype of primary viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 8 Mondo subtypes
  • Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameHerpesviridae infectious disease
Mondo IDMONDO:0005794
EFOEFO:0007309
MeSHD006566
SNOMED CT23513009
Is cancer (heuristic)no

Also known as: Herpesviridae caused disease or disorder · Herpesviridae disease or disorder · Herpesviridae infection · Herpesviridae infections · Herpesvirus infection · herpesvirus infection · Herpesvirus infections · infection, Herpesviridae · infection, Herpesvirus · infections, Herpesviridae · infections, Herpesvirus

Disease family

An umbrella term covering 8 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseaseviral infectious disease › primary viral infectious disease › Herpesviridae infectious disease

Related subtypes (31): plantar wart, monkeypox, smallpox, rubella, human papilloma virus infection, Rotavirus infection, Arenaviridae infectious disease, Astroviridae infectious disease, Caliciviridae infectious disease, cowpox, Flaviviridae infectious disease, Hepadnaviridae infectious disease, influenza, Mononegavirales infectious disease, Nidovirales infectious disease, phlebotomus fever, Picornaviridae infectious disease, polyomavirus infectious disease, Togaviridae infectious disease, viral encephalitis, viral hepatitis, viral pneumonia, viral exanthem, deltaretrovirus infections, Bunyaviridae infectious disease, viral sexually transmitted disease, lentivirus infection, viral myocarditis, viral pericarditis, adenoviridae infectious disease, aleutian mink disease, human

Subtypes (8): herpetic gastritis, herpes simplex infectious disease, Epstein-Barr virus infection, cytomegalovirus infection, human herpesvirus 8 infection, varicella zoster infection, roseolovirus infectious disease, congenital herpes virus infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified8
PHASE42

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00116844PHASE4COMPLETEDVALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
NCT00373165PHASE4COMPLETEDProphylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
NCT05198570Not specifiedRECRUITINGPharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
NCT00001156Not specifiedCOMPLETEDAssessment of Patients With Multiple Sclerosis (MS)
NCT00005496Not specifiedCOMPLETEDInflammation, Infection, and Future Cardiovascular Risk
NCT00026728Not specifiedCOMPLETEDSeroprevalence of Kaposi’s Sarcoma Herpes Virus in the United States
NCT00228670Not specifiedCOMPLETEDHerpesvirus in Idiopathic Pulmonary Fibrosis
NCT01248598Not specifiedUNKNOWNThe Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
NCT03051789Not specifiedCOMPLETEDCups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout
NCT04412811Not specifiedCOMPLETEDProspective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
GANCICLOVIR41
VALACYCLOVIR41